A recent cross-sectional study has evaluated the value of amyloid, tau, glucose hypometabolism, and structural atrophy in classifying MCI and AD patients, with amyloid and tau being better predictors of MCI and early AD, while glucose hypometabolism and atrophy were better predictors of later AD [41]. Here, MAPT is linked to Alzheimer disease.